



INTELLECTUAL VENTURES®

Intellectual Ventures and the University of British Columbia to Collaborate on Development of Novel Pelvic Fracture Treatment from the University and BC Cancer Agency

If successful, the new technology could result in faster recovery times for patients suffering from pelvic ring fractures.

VANCOUVER, B.C. and BELLEVUE, Wash. — November 6, 2012 — The Invention Development Fund of Intellectual Ventures (IV), The University of British Columbia (UBC) and BC Cancer Agency have entered into an agreement to further develop and commercialize a new pelvic fracture technology developed by clinicians and engineers at the BC Cancer Agency and Vancouver General Hospital. This minimally invasive technology can accelerate pelvic fracture treatment and recovery by replacing traditional screws used to fix pelvic ring fractures.

Under the agreement, the Invention Development Fund will provide funds to UBC that will support a clinical proof of concept of the technology. Following the proof of concept, the Invention Development Fund hopes to license the technology and associated intellectual property to a company that can bring the technology to market. By working with Intellectual Ventures, UBC and the BC Cancer Agency can more efficiently move their technology breakthrough beyond the research lab.

"This collaboration with Intellectual Ventures aims to enhance the commercialization pipelines available to UBC and its affiliated teaching hospitals and helps us achieve our goal of bringing world leading technologies to the marketplace for the betterment of society at large," said Angus Livingstone, Managing Director of UBC's University-Industry Liaison Office.

"Intellectual Ventures is proud of its ongoing collaboration with UBC, one of the world's leading research universities," said Eric Bell, Senior Director, Future Surgery Team at Intellectual Ventures. "IV is committed to the entire invention life-cycle, including building, refining, and testing the best inventions and then bringing them to the functional prototype stage and beyond. This unique agreement with UBC helps us make our long-term vision a reality."

About Intellectual Ventures

Founded in 2000, Intellectual Ventures (IV) is the global leader in the business of invention. IV collaborates with leading inventors, partners with pioneering companies, and invests both expertise and capital in the process of invention. IV's mission is to energize and streamline an invention economy that will drive innovation around the world. For more information, please visit www.intellectualventures.com, follow IV on Twitter at [@IVinvents](https://twitter.com/IVinvents) and "like" IV on Facebook at facebook.com/intven.

About The University of British Columbia's University-Industry Liaison Office (UILO)

The UILO supports interaction between the University and industry and other community partners in many different forms, including research partnerships that investigate areas of mutual interest, the commercialization, distribution and dissemination of research outputs, and the development of entrepreneurial talent and new ventures. Each year researchers at UBC and its Affiliated Teaching Hospitals engage in approximately 1,000 research collaborations with industry partners. Discoveries made at UBC and its Affiliated Teaching Hospitals have been the basis of more than 150 spin-off companies and products that have generated more than \$5 billion in sales. For more information, visit: www.uilo.ubc.ca

For more information:

Intellectual Ventures

For press inquiries, please contact press@intven.com. For all other inquiries, please contact info@intven.com or follow IV on Twitter at [@IVinvents](https://twitter.com/IVinvents).

University of British Columbia
Jamie Hall
UBC University-Industry Liaison Office
jamie.hall@uilo.ubc.ca
604 742 1370

Intellectual Ventures and IV are registered trademarks of Intellectual Ventures Management, LLC,
its subsidiaries or related companies (IV).

All other trademarks are the property of their respective owners.